<DOC>
	<DOCNO>NCT00207805</DOCNO>
	<brief_summary>Autologous peripheral blood stem cell ( PBSC ) transplantation consider standard therapy patient ( &lt; 65 an ) multiple myeloma . The Intergroupe Francophone du Myelome conduct randomised trial treatment multiple myeloma high dose chemotherapy follow either one two successive autologous stem cell transplantation . The probability event-free-survival overall survival double double transplant . The benefit great among patient good partial response first transplant . The aim multicenter randomise trial previously untreated patient multiple myelome ( stage II , III DS ) ass optimal time second autologous stem-cell transplant.After first-line therapy thalidomide-dexamethasone follow PBSC collection , patient randomly assign receive two autologous PBSC transplant ( arm A ) one autologous PBSC transplant follow consolidation therapy thalidomide-dexamethasone ( arm B ) . Patients include arm B receive second transplant case disease progression consolidation therapy , case relapse responder .</brief_summary>
	<brief_title>The Optimal Timing Second Autologous Peripheral Blood Stem Cell Transplantation Patients ( &lt; 61 Years ) With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>patient le 61 year age Durie Salmon stage II III write informed consent Prior treatment myeloma ECOG performance score 4 Positive HIV test Chronic respiratory disease ( DLco &lt; 60 % ) Systolic ejection fraction &lt; 50 % Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>January 2009</verification_date>
</DOC>